Get the Stockscreener App
2.06
2.37%
-0.05
After Hours:
2.06
Maxcyte Inc stock is traded at $2.06, with a volume of 400.94K.
It is down -2.37% in the last 24 hours and down -5.50% over the past month.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
See More
Previous Close:
$2.11
Open:
$2.08
24h Volume:
400.94K
Relative Volume:
0.47
Market Cap:
$219.22M
Revenue:
$45.44M
Net Income/Loss:
$-35.43M
P/E Ratio:
-6.0588
EPS:
-0.34
Net Cash Flow:
$-25.39M
1W Performance:
-9.25%
1M Performance:
-5.50%
6M Performance:
-54.32%
1Y Performance:
-57.08%
1-Day Range:
$2.02
$2.1009
1-Week Range:
$2.02
$2.305
52-Week Range:
$2.00
$5.20
Maxcyte Inc Stock (MXCT) Company Profile
Name
Maxcyte Inc
Sector
Industry
Phone
301-517-5556
Address
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
2.06 | 224.33M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
126.19 | 223.66B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
104.92 | 157.95B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
392.73 | 153.02B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
90.24 | 117.42B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
79.31 | 47.61B | 5.69B | 4.15B | 623.10M | 6.95 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-25 | Initiated | Stephens | Overweight |
| Nov-29-23 | Initiated | Craig Hallum | Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-24-21 | Initiated | BTIG Research | Buy |
| Aug-24-21 | Initiated | Cowen | Outperform |
| Aug-24-21 | Initiated | Stephens | Overweight |
| Aug-24-21 | Initiated | Stifel | Buy |
| Aug-24-21 | Initiated | Wedbush | Outperform |
| Aug-24-21 | Initiated | William Blair | Outperform |
View All
Maxcyte Inc Stock (MXCT) Latest News
Exit strategy if you’re trapped in MaxCyte Inc.Chart Risk Profile for Capital Preservation - Newser
MaxCyte announces strategic platform licensing agreement with Anocca AB to advance TCR-T cell therapy pipeline - MarketScreener
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline - The Manila Times
MaxCyte Expands Cell Therapy Reach: Strategic License Deal Powers Anocca's TCR-T Pipeline - Stock Titan
Visual analytics tools that track MaxCyte Inc. performanceDay Trading Setup Forecast with Trend Model - Newser
MaxCyte Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingFree Wealth Building Stock Market Ideas - Newser
Should I hold or sell MaxCyte Inc. stock in 2025Beginner Investor Planner With Low Risk - jammulinksnews.com
Chart based exit strategy for MaxCyte Inc.Stable Profit Zone and Loss Control Analysis - Newser
What makes MaxCyte Inc. stock price move sharplyChart Driven Entry Timing for Swing Trades - Newser
Leading vs lagging indicators on MaxCyte Inc. performanceGrowth Projection Summary for Long-Term Investors - Newser
How MaxCyte Inc. stock performs during market volatilityCapital Growth With Controlled Risk Picks Suggested - metal.it
Signal strength of MaxCyte Inc. stock in tech scannersWeekly Growth Portfolio Performance Summary - Newser
MaxCyte Inc. Approaches Support With Recovery in SightConservative Entry for High Return Setup Backed - metal.it
Why MaxCyte Inc. stock attracts strong analyst attentionCommunity Shared Smart Money Signals Show Movement - metal.it
New York State Common Retirement Fund Raises Stock Position in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
Is MaxCyte Inc. a growth stock or a value stockGet daily expert analysis for smarter investing - jammulinksnews.com
What is the dividend policy of MaxCyte Inc. stockGet daily updates on promising stocks - jammulinksnews.com
What institutional investors are buying MaxCyte Inc. stockMaximize portfolio growth with professional advice - jammulinksnews.com
MaxCyte Inc. Company’s Quarterly Earnings Growth: What the Numbers SayDaily Gain Forecast - metal.it
How does MaxCyte Inc. compare to its industry peersBuild a winning portfolio with smart picks - jammulinksnews.com
What drives MaxCyte Inc. stock priceHigh-yield investments - PrintWeekIndia
MaxCyte (NASDAQ:MXCT) Research Coverage Started at Stephens - Defense World
What makes MaxCyte Inc. stock attractive to long term investorsRapid growth trajectories - jammulinksnews.com
Is MaxCyte Inc. a good long term investmentHigh-return market picks - PrintWeekIndia
What analysts say about MaxCyte Inc. stockRapid portfolio appreciation - Autocar Professional
MaxCyte Inc. Stock Analysis and ForecastSuperior risk-adjusted returns - Autocar Professional
Published on: 2025-07-23 21:52:41 - Autocar Professional
Maxcyte Inc Stock (MXCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):